Information Provided By:
Fly News Breaks for July 8, 2019
QURE
Jul 8, 2019 | 07:01 EDT
Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure to $94 from $81 after the company over the weekend presented nine-month data from the Phase 2b trial of AMT-061 in hemophilia B. The analyst remains optimistic that uniQure has the "best-in-class" hemophilia B gene therapy product. Further, he thinks new interest could emerge from the company's pipeline beyond hemophilia B this year. Piros reiterates an Overweight rating on uniQure shares.
News For QURE From the Last 2 Days
There are no results for your query QURE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.